Intraindividual comparisons showed that ABRs for untreated bleeds decreased for people with hemophilia A of all ages with FVIII inhibitors when they transitioned from the NIS to the respective HAVEN study, but remained fairly constant for those without FVIII inhibitors. This evidence concerns the gene F8 and hemophilia A.